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Introduction
‘A picture is worth a thousand words’ is an idiom from
the English language (‘borrowed’ from on old Chinese
proverb) that conveys the notion that a complex idea
can be succinctly and fully described by a single image.
Never has this expression been truer than in the clinical
and pharmaceutical arenas. Enormous strides have been
made by the scientific community in the evolving field
of biomedical imaging with the aim of representing and/
or quantifying aspects of disease and drug action by
using tools such as radiography [1], MRI [2, 3] PET [4],
and ultrasound [5]. Yet linking the phenotypical data
generated by these systems to the genome is a challen-
ging task. Identifying the link between the mechanism of
disease or failed drug response to the genome of an indi-
vidual is difficult, because central pieces of information
are missing. However, imaging mass spectrometry (IMS)
can overcome this issue. IMS aims to detect the molecu-
lar constituents of the tissue; these can then be corre-
lated with genome-related characteristics, such as gene
expression patterns and possible mutations, and ultim-
ately provide a phenotypic molecular link to the com-
plex disease biology. The big data technology of IMS can
generate spatial information of thousands of metabolites
and proteins from within a tissue, facilitating a deeper
understanding of the connections between the genome,
phenotypic characteristics and the biological response. It
is a technology that has the potential to serve as a segue
between gene expression and observed biological signal.
Image analysis has been a focus of mass spectrometry
for more than 40 years since early studies using secondary
ion mass spectrometry (SIMS) [6]. Among the several
ionization techniques, matrix-assisted laser desorption
ionization (MALDI) imaging mass spectrometry is the
leader for analyzing molecular distributions within tissues
[7]. MALDI IMS is capable of mapping biomolecules of
interest at high spatial resolution (~ 1 μm), and high sensi-
tivity. It can be employed to image a broad variety of
molecular classes, from low-molecular-weight metabo-
lites, lipids (> 1 kDa) and proteins [8, 9]. The unique
ability of this technique to reveal these ionized molecular
entities, while retaining the spatial information for
multiple molecules in one measurement, makes histology-
directed MALDI IMS a powerful tool for clinical applica-
tions and genome-based personalized medicine [10].
Furthermore, desorption electrospray ionization (DESI)
[11] is an ionization technique that has the capability of
direct solid surface sampling under open ambient condi-
tions. DESI has the advantages of ambient ionization
methods and combined with MALDI, hundreds-to-
thousands of molecules can be evaluated simultaneously
and their spatial distribution can be visualized from within
the same tissue section (Table 1). Consequently, the
molecular changes in a tissue can be accurately studied,
correlated to images and cellular features generated by
traditional histology, and the pathogenic mechanisms of a
certain disease can be visualized and identified, leading to
the potential discovery of new biomarkers [8].
The pharmaceutical industry has taken advantage of
the development of IMS to enable an array of high-
throughput screening modalities for pharmaceutical as-
sessments [12]. IMS can provide reliable, label-free
qualitative and quantitative distribution information for
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a drug of interest and its subsequent biotransformed
metabolites [13]. This information can be used to deter-
mine and understand the pharmacokinetic (PK) proper-
ties of a drug, its penetration into tissue, and to assess
drug efficacy and potential toxicity [14]. This makes
IMS a powerful, yet cost-effective technology because
distribution studies can be performed earlier in the
drug discovery process without any requirement for
radiolabeled standards. Of critical importance, IMS
separately maps and differentiates drug from its
metabolites, rather than tracking just a radiolabeled
parent drug [14–16].
At this 1-day symposium, the Department of
Environmental Health Sciences (DEHS) at the Yale
School of Public Health brought together leaders in
IMS to discuss recent developments, limitations, and
future needs, and to increase awareness of this grow-
ing and important field. During his opening remarks,
Dr. Vasiliou highlighted the potential of IMS to define
the molecular basis of diseases, to provide insights
into mechanisms, and to integrate tissue morphology
at the molecular level. Thereafter, talks by an impres-
sive assembly of thought-leaders in IMS illustrated the
potential of unbiased tissue imaging to deliver a new
level of understanding of pathophysiological processes
at the molecular level. The symposium concluded with
a round-table discussion, chaired by Dr. Mark Dun-
can, on some of the more practical issues in IMS such
as current bottlenecks and future opportunities. The
presentations and discussions at the symposium
underscored the great potential of IMS. With the
intention of bringing IMS to the larger scientific com-
munity, the DEHS has committed significant resources
to the acquisition of equipment and expertise that will
allow the further development and application of IMS
techniques.
MALDI imaging mass spectrometry (IMS): recent
technological advances
The first talk of the symposium was given by a pioneer of
the field, Dr. Richard Caprioli, Professor of Biochemistry
and Director of the Mass Spectrometry Research Center
at Vanderbilt University. His opening remarks gave a his-
torical overview of MALDI IMS technology and empha-
sized its advantages. Dr. Caprioli explained how MALDI
IMS employs desorption of molecules by direct laser
irradiation to map the location of specific molecules from
fresh frozen or formalin-fixed tissue sections without the
need to target specific reagents, such as antibodies [17].
Dr. Caprioli championed the major benefits of the
histology-directed approach (that has been developed by
his group) over conventional staining and microscopic
methods. This technology is an addition to the histologist’s
toolbox, not a replacement. By integrating microscopy
with MALDI IMS, this application is almost limitless and
could be used in a variety of biologically and medically
relevant research projects. Dr. Caprioli highlighted studies
in diabetic nephropathy involving both proteins and lipids
and the differentiation of benign skin lesions from
melanomas [17, 18]. In addition, Dr. Caprioli’s group has
applied IMS to drug targeting and metabolic studies in
specific organs and in intact whole animal sections follow-
ing drug administration [19]. Recent technological
advances were also described for sample preparation to
improve metabolite extraction and instrument perform-
ance to achieve images at high spatial resolution (1–
10 μm) and at high speeds so that a typical sample tissue,
once prepared, can be imaged in minutes [20]. Instrumen-
tation used in these studies included both MALDI fourier
transform ion cyclotron resonance (FTICR) and MALDI
time-of-flight (TOF) mass spectrometers. Applications
utilize tandem mass spectrometry (MS/MS), ultra-high
mass resolution, and ion accumulation devices for IMS
Table 1 Imaging mass spectrometry ionization techniques: application, advantages, and disadvantages [8, 9, 11].
Application Ionization Advantages Disadvantages
Tissue molecular imaging MALDI • Label-free analysis
• High-sensitivity
• Use over a broad mass range
• High-spatial resolution (≤ 1 μm)
• Application on both formalin-fixed
paraffin-embedded (FFPE) tissue
microarrays and on fresh tissue samples.
• Low throughput
• Sample preparation can lead to spatial
dislocation or chemical modifications
• Matrix dependent analysis
DESI • Label-free analysis
• Ambient ionization method
• Direct solid surface sampling
• Multiple charged ions
• Minimal sample preparation
• Soft ionization method
• Generally less costly upon comparison
to MALDI
• Imaging in the low-mass region—limited
use for proteins
• Poorer spatial resolution compared
to MALDI
• Solvent dependent
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studies. Finally, new biocomputational approaches were
discussed that are required to handle the high-data dimen-
sionality of IMS, and also ‘image fusion’ for predictive
integration of mass spectrometry (MS) images with mi-
croscopy and other imaging modalities [21].
Dr. Kevin Schey, Professor of Biochemistry, Ophthal-
mology and Visual Sciences, at Vanderbilt University,
discussed the application of IMS to study a range of mo-
lecular classes, such as proteins, lipids, and metabolites
in ocular tissues. Ocular tissues provide an ideal medium
to demonstrate the utility of the technique where mor-
phological features are on the scale of single cells. For
example, molecular profiles can be produced in retina
pigment epithelium. Moreover, a range of diseases affect
the various ocular tissues, including glaucoma, age-
related macular degeneration, cataract, and corneal cata-
ract. Dr. Schey illustrated how IMS is being actively ap-
plied to derive mechanistic information that enhances
understanding about the molecular underpinnings of
disease in these tissues as well as aging mechanisms.
IMS data from optic nerve, retina, lens, and cornea were
presented with special attention to diseases affecting
these tissues [22]. Data from both animal models of dis-
ease and human tissues were discussed, as well as key
methodological details for successful imaging ocular tis-
sues [23–25]. Dr. Schey’s work, in collaboration with Dr.
Vasiliou, on a corneal haze phenotype in Aldh3a1-null
mice presented the first genetic animal model of
cellular-induced corneal haze due to the loss of a corneal
crystallin [24]. This work clearly showed how IMS can
provide deeper understanding for the genome, linking
the disease phenotype with genetic changes.
The broad range of IMS applications was reinforced
even more by Dr. Andrén, Professor at Uppsala Univer-
sity, who showed novel ways to interrogate the actions
of neurotransmitters, their precursors and metabolites,
in the brain chemical network and neuronal signal trans-
mission [26]. Changes in neurotransmitter concentra-
tions are associated with numerous normal neuronal
processes, such as sleep and aging, and in several disease
states, including neurological disorders (e.g., Parkinson’s
and Alzheimer’s disease), depression, and drug addiction.
Dr. Andrén uses knowledge about the relative abun-
dance and spatial distribution of neurotransmitters in
the brain to provide insights into these complex neuro-
logical processes and disorders. At present, researchers
rely on indirect histochemical, immunohistochemical,
and ligand-based assays to detect small-molecule trans-
mitter substances or on tissue homogenates analyzed by
high-performance liquid chromatography analysis.
Current neuroimaging techniques have very limited cap-
acities to directly identify and quantify neurotransmitters
from brain sections. MALDI IMS can perform analyses
directly on the surface of a tissue section, establishing
itself as a powerful in situ visualization tool for measuring
abundance and spatial distribution of endogenous and
pharmaceutical compounds, lipids, peptides, and small pro-
teins. A novel reactive MALDI matrix, recently developed
by Dr. Andrén’s group, selectively targets the primary amine
group on neurotransmitters, metabolites, and neuroactive
substances while also functioning as a matrix to enable
ionization [27]. However, the limitation of using such a re-
active matrix to study the full molecular pathways of, for
example, dopaminergic or serotonergic biosynthesis and
metabolism is its limitation to target all downstream dopa-
mine metabolites derived from monoamine oxidase (MAO)
or catechol-O-methyltransferase (COMT) enzymes. The
majority of small molecule neurotransmitters, such as cate-
cholamines, amino acids, and trace amines, possess phen-
olic hydroxyl and/or primary or secondary amines which
are strong nucleophilic groups. Dr. Andrén’s laboratory has
therefore developed a new reactive matrix that can select-
ively target and charge-tag both phenolic and primary
amine groups, thus enabling MALDI IMS of both MAO
and COMT downstream metabolites, focusing on a nucleo-
philic aromatic substitution reaction with such functional
groups. Using this new reactive matrix, they were able to
detect and map the localization of most of the neurotrans-
mitters and metabolites involved in the dopaminergic and
serotonergic network in a single brain tissue section. This
work showed a novel methodology that assists with metab-
olite identification through the selectivity of the reaction.
The sensitivity and specificity of this imaging approach to
neurochemicals has great potential for many diverse appli-
cations in neuroscience, pharmacology, drug discovery,
neurochemistry, and medicine.
Visualizing drug disposition in tissue
A major focus of the symposium was the application of
MALDI IMS to map the distribution of a variety of
therapeutic molecules across a tissue section of interest
and to assess their biological impact.
Current president of the Imaging Mass Spectrometry
Society and director of US Imaging MS, at GlaxoS-
mithKline (GSK), Dr. Castellino, discussed how MALDI
IMS technology has taken their research beyond
“plasma-centric” studies and allowed for direct mapping
of molecular changes in tissue associated with drug
pharmacology, disposition, and disease pathogenesis.
Delivering safe and efficacious drugs is tied to the ability
to understand complex mechanistic relationships be-
tween molecular initiation events of pharmacologically
active compounds and the cascade of subsequent bio-
logical consequences. Because the delivery of drugs to
their intended target, and avoidance of unintended
targets, is a critical first step, IMS can directly guide
improvements and innovation in delivery strategies by
mapping the target tissue selectivity [28]. Furthermore,
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tissue correlations can be directly made to plasma PK or
lead to improved pharmacodynamic understanding. Dr.
Castellino’s group has explored the use of MALDI IMS
to investigate the distribution of drugs and their metabo-
lites, as well as endogenous compounds, in a wide
variety of target tissues in support of numerous thera-
peutic areas and in all drug discovery and development
stages [29, 30]. The IMS methodology allows for the
co-registration of drug analytes in tissue distributions
with histology images, thereby integrating chemical
structures with tissue morphology. Furthermore, this im-
aging modality offers the potential to further our mech-
anistic understanding of drug disposition, disease
progression, and pharmacology (including toxicology) by
providing snap shots of temporal and causal changes
[31]. Dr. Castellino continued, that while MALDI IMS is
primarily being employed to determine the tissue distri-
bution of drugs and their metabolites, it has become
evident that more detailed understanding of biological
systems can be gained by including the changes in
endogenous compound distribution as a function of
disease and pharmacology. Closing his presentation, Dr.
Castellino discussed the importance of suitable software
tools and improved data handling methods needing to
be developed alongside analytical progress in order for
the full potential of MALDI IMS to be realized.
Dr. Richard Goodwin, a principal scientist for Drug
Safety and Metabolism at AstraZeneca (AZ) and head of
mass spectrometry imaging, presented the challenges
faced for drug discovery and development; it is a
lengthy, high risk, and competitive business that can
take a decade to progress; moreover, billions of dollars
are required to move a new medicine to market. Dr.
Goodwin discussed how IMS could help mitigate some
of the primary reasons for drug attrition, specifically
around lack of efficacy and toxicological or clinical safety
risk. IMS is now demonstrating impact on drug discov-
ery programs and helping reduce later stage compound
attrition. It provides insights into the biodistribution of
compounds, while simultaneously generating data on
pharmacodynamic biomarkers. Dr. Goodwin presented
data from AZ that showed how the use of a range of
multimodal imaging techniques improves understanding
about compound efficacy, safety, and targeted drug
delivery [32, 33]. Investigating histopathological-targeted
drug-induced toxicity is now readily achieved using
high-spatial resolution and high-mass resolution IMS.
Dr. Goodwin outlined how a Cancer Research UK Grand
Challenge consortium are seeking to use multimodal
IMS to offer new insights into tumor metabolism and to
help develop new, more effective medicines and therapy
combinations. The $20 million project led by Professor
Bunch at the National Physical Laboratory UK (in col-
laboration with world leading oncology biologists, IMS
technologists, and AZ) will utilize data similar to that
shared at the symposium. IMS can help identify metab-
olite changes consistent with the biomarker changes in
the tumor and show changes in metabolites as PD bio-
markers, hence providing valuable new insights into the
pathway and drug combinations. The next hurdle is how
to effectively mine multimodal imaging data. Recent
strategies on data processing and visualization as well as
data mining algorithms were outlined [34]. In his closing
remarks, Dr. Goodwin highlighted the challenges and
opportunities arising from the significant quantities of
molecular imaging data generated, from a cellular to
patient level.
Dr. Sheerin Shahidi-Latham, Head of Metabolomics
and Imaging MS, Department of Drug Metabolism and
Pharmacokinetics at Genentech Inc., also discussed the
advantages of the applied use of MALDI IMS. In the
pharmaceutical industry, obtaining information about
the absorption, distribution, metabolism, and elimination
(ADME) of a new chemical entity via a PK study in a
preclinical animal model is often the first step towards
understanding the in vivo properties of a drug-like
molecule in humans. Traditionally, much of this ADME
work has been supported by liquid-chromatography
coupled to mass spectrometry. In the case of tissue
distribution, the organs are excised and homogenized in
order to accommodate this analytical workflow, thereby
effectively eliminating any spatial information. Dr.
Shahidi-Latham emphasized that MALDI IMS has
gained prominence since it provides a robust, label-free
detection of drug and metabolites while preserving
spatial localization within tissue sections of interest.
Additionally, the use of high-resolution mass spectrome-
ters has provided the opportunity for simultaneous de-
tection of subsequent pharmacodynamic (PD) responses
within a single image acquisition. Dr. Shahidi-Latham
discussed how the ability to assess PK/PD relationships
in a label-free, in situ context has proven invaluable to
the early lead optimization efforts that take place in the
drug discovery setting. Similarly, uncovering the perpet-
rator of adverse effects often associated with histopatho-
logical assessments in the preclinical development phase
has also improved their understanding about the mecha-
nisms of toxicity and can provide useful information for
the redesign of a back-up molecule. The presentation
provided a synopsis of the advantages of IMS, as well as
the technical challenges and opportunities in the context
of the pharmaceutical industry. Dr. Shahidi-Latham
presented data from her work at Genentech, which in-
cluded MALDI IMS of dosed tissues in support of drug
efficacy, PK/PD, and effective delivery evaluations, and
highlighted the simultaneous detection of drug, metabo-
lites, and endogenous components attainable from a sin-
gle imaging run [35–39]. Moreover, examples
Charkoftaki et al. Human Genomics  (2018) 12:10 Page 4 of 6
demonstrating the utility of imaging MALDI IMS for
toxicity screening were presented. Its complementary
use with autoradiography analyses were discussed, in-
cluding ocular drug distribution and whole-body drug
disposition studies [15].
Bioinformatics platform for large-scale mass
spectrometry imaging data
The constant drive towards integrating complex and large-
scale datasets has generated the need to develop new tools
to process this information [40]. Dr. Kirill Veselkov, Lec-
turer at Imperial College London, discussed how managing,
analyzing, and interpreting these data are a challenge and a
major barrier to their clinical translation. IMS augments
digital pathologic analysis with highly robust big data on
cellular metabolic and proteomic molecular content, gener-
ating a staggering amount of unrefined data (tens to hun-
dreds of gigabytes of data per tissue section). Existing data
analysis solutions for IMS rely on a set of heterogeneous
bioinformatics packages that are not scalable for the repro-
ducible processing of large-scale (hundreds to thousands)
biological sample sets. In this talk, Dr. Veselkov presented a
computational platform (pyBASIS) capable of optimized
and scalable processing of IMS data for improved informa-
tion recovery and comparative analysis across tissue speci-
mens using machine learning and related pattern
recognition approaches. The proposed solution also
provides a means of seamlessly integrating experimental
laboratory data with downstream bioinformatics interpret-
ation and analyses, resulting in a truly high-throughput
system for translational IMS.
The symposium concluded with a round-table discus-
sion, chaired by Dr. Mark Duncan, where the attendees
discussed the practical challenges and future directions of
IMS. The attendees not only agreed on the potential of
IMS to provide previously inaccessible insights into mo-
lecular events at the tissue level, but also highlighted the
cost and complexity of both the science and the technol-
ogy that underpins these studies. Rather than a routine
core service, it was agreed that designing meaningful stud-
ies, performing exacting sample handling, generating and
interpreting complex data, and maintaining high-end in-
strumentation requires a substantial, highly collaborative
interaction between all stakeholders.
Abbreviations
ADME: Absorption, distribution, metabolism, and elimination;
COMT: Catechol-O-methyltransferase; DESI: Desorption electrospray
ionization; IMS: Imaging mass spectrometry; MALDI: Matrix-assisted laser
desorption ionization; MAO: Monoamine oxidase; MS: Mass spectrometry;
PD: Pharmacodynamic; PK: Pharmacokinetic
Acknowledgements
We would like to thank the Yale Cancer Center, Genentech Inc., and the
Waters Corporation for their support and sponsorship for the Symposium.
Special thanks to Drs. Dustin Yaworsky and Ray Chen (Waters Corp.). We
would also like to thank Dr. David Thompson (University of Colorado Denver)
for his invaluable input. We would also like to thank Ms. Donna Cropley and Ms.
Damaris Faustine for their crucial help in organizing the symposium.
Funding
The authors would like to acknowledge the following funding sources: NIH
R01 EY017963 (VV), NIH R24 AA022057 (VV), Women’s Health Research at Yale
(CHJ), Yale Comprehensive Cancer Center (CHJ).
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or
analyzed during the current study.
Authors’ contributions
GC participated in writing the introduction, the conclusions, drafted and
edited the manuscript. NJWR participated in writing the introduction and
editing the manuscript. CHJ participated in editing the manuscript. MWD
participated in editing the manuscript. Section: “MALDI Imaging Mass
Spectrometry (IMS): recent technological advances”: RMC wrote the
paragraph about the MALDI IMS advantages, explaining how this technique
employs desorption of molecules by direct laser irradiation to map the
location of specific molecules. KLS wrote the paragraph about the
application of IMS to study a range of molecular classes, such as proteins,
lipids, and metabolites in ocular tissues. PEA wrote the part about the novel
ways to interrogate the actions of neurotransmitters, their precursors, and
metabolites. Section: “Visualizing drug disposition in tissue”: SC wrote the
paragraph discussing how MALDI IMS technology has taken their research
beyond “plasma-centric” studies and allowed for direct mapping of
molecular changes in tissue associated with drug pharmacology, disposition,
and disease pathogenesis. RJAG presented the challenges faced for drug
discovery and development. SKSL wrote about the advantages of the
applied use of MALDI IMS in the pharmaceutical industry. KAV wrote the
“Bioinformatics platform for large-scale mass spectrometry imaging data”
section. VV conceived of the IMS Symposium, participated in its design and
coordination, and helped to draft and edit the manuscript. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Environmental Health Sciences, Yale School of Public Health,
Yale University, New Haven, USA. 2Biomolecular Mass Spectrometry Imaging,
National Resource for Mass Spectrometry Imaging, Department of
Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
3Departments of Biochemistry and the Mass Spectrometry Research Center,
Vanderbilt University School of Medicine, Nashville, USA. 4Department of
Bio-Imaging, Platform Science and Technology, GSK, King of Prussia, USA.
5Biodesix Inc., Boulder, USA. 6Pathology, Drug Safety and Metabolism, IMED
Biotech Unit, AstraZeneca, Cambridge, UK. 7Departments of Biochemistry and
Ophthalmology and Visual Sciences, Vanderbilt University School of
Medicine, Nashville, USA. 8Department of Drug Metabolism and
Pharmacokinetics, Genentech, Inc., South San Francisco, USA. 9Computational
and Systems Medicine, Department of Surgery and Cancer, Faculty of
Medicine, Imperial College London, London, UK. 10Yale Cancer Center, Yale
School of Medicine, Yale University, New Haven, USA. 11Department of
Ophthalmology and Visual Science, Yale School of Medicine, Yale University,
New Haven, USA.
Charkoftaki et al. Human Genomics  (2018) 12:10 Page 5 of 6
Received: 8 January 2018 Accepted: 18 February 2018
References
1. Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, Hricak H, Sutton EJ,
Morris EA. Background, current role, and potential applications of
radiogenomics. J Magn Reson Imaging. 2018;47(3):604–20.
2. Fetit AE, Novak J, Rodriguez D, Auer DP, Clark CA, Grundy RG, Peet AC,
Arvanitis TN. Radiomics in paediatric neuro-oncology: a multicentre study
on MRI texture analysis. NMR Biomed. 2018;31(1). https://doi.org/10.1002/
nbm.3781.
3. Verbeeck N, Spraggins JM, Murphy MJM, Wang HD, Deutch AY, Caprioli RM,
Van de Plas R. Connecting imaging mass spectrometry and magnetic
resonance imaging-based anatomical atlases for automated anatomical
interpretation and differential analysis. Biochim Biophys Acta. 1865;2017:
967–77.
4. Collier TL, Maresca KP, Normandin MD, Richardson P, McCarthy TJ, Liang SH,
Waterhouse RN, Vasdev N. Brain penetration of the ROS1/ALK inhibitor
Lorlatinib confirmed by PET. Mol Imaging. 2017;16:1536012117736669.
5. Guo R, Lu G, Qin B, Fei B. Ultrasound imaging Technologies for Breast
Cancer Detection and Management: a review. Ultrasound Med Biol. 2018;
44(1):37–70.
6. Castaing RSG. Microanalysis by secondary ionic emission. J Microsc. 1962;1:
395–410.
7. Schwamborn K, Caprioli RM. Molecular imaging by mass
spectrometry—looking beyond classical histology. Nat Rev Cancer. 2010;10:
639–46.
8. Caprioli RM. Imaging mass spectrometry—molecular microscopy for
biological and clinical research. In: Banoub JH, Caprioli RM, editors.
Molecular Technologies for Detection of chemical and biological agents.
Dordrecht: Springer Netherlands; 2017. p. 115–32.
9. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples:
localization of peptides and proteins using MALDI-TOF MS. Anal Chem.
1997;69:4751–60.
10. Duarte TT, Spencer CT. Personalized proteomics: the future of precision
medicine. Proteomes. 2016;4(4):29.
11. Takats Z, Wiseman JM, Gologan B, Cooks RG. Mass spectrometry sampling
under ambient conditions with desorption electrospray ionization. Science.
2004;306:471–3.
12. Swales JG, Tucker JW, Strittmatter N, Nilsson A, Cobice D, Clench MR,
Mackay CL, Andren PE, Takats Z, Webborn PJ, Goodwin RJ. Mass
spectrometry imaging of cassette-dosed drugs for higher throughput
pharmacokinetic and biodistribution analysis. Anal Chem. 2014;86:8473–80.
13. Swales JG, Strittmatter N, Tucker JW, Clench MR, Webborn PJ, Goodwin RJ.
Spatial quantitation of drugs in tissues using liquid extraction surface
analysis mass spectrometry imaging. Sci Rep. 2016;6:37648.
14. Barry JA, Groseclose MR, Robichaud G, Castellino S, Muddiman DC.
Assessing drug and metabolite detection in liver tissue by UV-MALDI and
IR-MALDESI mass spectrometry imaging coupled to FT-ICR MS. Int J Mass
Spectrom. 2015;377:448–155.
15. Shahidi-Latham SK, Dutta SM, Prieto Conaway MC, Rudewicz PJ. Evaluation
of an accurate mass approach for the simultaneous detection of drug and
metabolite distributions via whole-body mass spectrometric imaging. Anal
Chem. 2012;84:7158–65.
16. Goodwin RJ, Nilsson A, Mackay CL, Swales JG, Johansson MK, Billger M,
Andren PE, Iverson SL. Exemplifying the screening power of mass
spectrometry imaging over label-based technologies for simultaneous
monitoring of drug and metabolite distributions in tissue sections. J Biomol
Screen. 2016;21:187–93.
17. Prentice BM, Caprioli RM, Vuiblet V. Label-free molecular imaging of the
kidney. Kidney Int. 2017;92:580–98.
18. Lazova R, Yang Z, El Habr C, Lim Y, Choate KA, Seeley EH, Caprioli RM,
Yangqun L. Mass spectrometry imaging can distinguish on a proteomic
level between proliferative nodules within a benign congenital nevus and
malignant melanoma. Am J Dermatopathol. 2017;39:689–95.
19. Seeley EH, Caprioli RM. 3D imaging by mass spectrometry: a new frontier.
Anal Chem. 2012;84:2105–10.
20. Prentice BM, Chumbley CW, Caprioli RM. High-speed MALDI MS/MS
imaging mass spectrometry using continuous raster sampling. J Mass
Spectrom. 2016;51:665.
21. Van de Plas R, Yang J, Spraggins J, Caprioli RM. Image fusion of mass
spectrometry and microscopy: a multimodality paradigm for molecular
tissue mapping. Nat Methods. 2015;12:366–72.
22. Anderson DMG, Lambert W, Calkins DJ, Ablonczy Z, Crouch RK, Caprioli RM,
Schey KL. Imaging MS of rodent ocular tissues and the optic nerve.
Methods Mol Biol. 1618;2017:15–27.
23. Wang Z, Schey KL. Identification of a direct Aquaporin-0 binding site in the
lens-specific cytoskeletal protein filensin. Exp Eye Res. 2017;159:23–9.
24. Chen Y, Jester JV, Anderson DM, Marchitti SA, Schey KL, Thompson DC, Vasiliou V.
Corneal haze phenotype in Aldh3a1-null mice: in vivo confocal microscopy and
tissue imaging mass spectrometry. Chem Biol Interact. 2017;276:9–14.
25. de Macedo CS, Anderson DM, Schey KL. MALDI (matrix assisted laser
desorption ionization) imaging mass spectrometry (IMS) of skin: aspects of
sample preparation. Talanta. 2017;174:325–35.
26. Shariatgorji M, Strittmatter N, Nilsson A, Kallback P, Alvarsson A, Zhang X,
Vallianatou T, Svenningsson P, Goodwin RJ, Andren PE. Simultaneous imaging of
multiple neurotransmitters and neuroactive substances in the brain by desorption
electrospray ionization mass spectrometry. NeuroImage. 2016;136:129–38.
27. Shariatgorji M, Nilsson A, Goodwin RJ, Kallback P, Schintu N, Zhang X,
Crossman AR, Bezard E, Svenningsson P, Andren PE. Direct targeted
quantitative molecular imaging of neurotransmitters in brain tissue sections.
Neuron. 2014;84:697–707.
28. Groseclose MR, Laffan SB, Frazier KS, Hughes-Earle A, Castellino S. Imaging
MS in toxicology: an investigation of juvenile rat nephrotoxicity associated
with Dabrafenib administration. J Am Soc Mass Spectrom. 2015;26:887–98.
29. Jucker BM, Alsaid H, Rambo M, Lenhard SC, Hoang B, Xie F, Groseclose MR,
Castellino S, Damian V, Bowers G, Gupta M. Multimodal imaging approach
to examine biodistribution kinetics of Cabotegravir (GSK1265744) long
acting parenteral formulation in rat. J Control Release. 2017;268:102–12.
30. Brown HR, Castellino S, Groseclose MR, Elangbam CS, Mellon-Kusibab K,
Yoon LW, Gates LD, Krull DL, Cariello NF, Arrington-Brown L, et al. Drug-induced
liver fibrosis: testing Nevirapine in a viral-like liver setting using histopathology,
MALDI IMS, and gene expression. Toxicol Pathol. 2016;44:112–31.
31. Groseclose MR, Castellino S. A mimetic tissue model for the quantification
of drug distributions by MALDI imaging mass spectrometry. Anal Chem.
2013;85:10099–106.
32. Nilsson A, Peric A, Strimfors M, Goodwin RJA, Hayes MA, Andren PE,
Hilgendorf C. Mass spectrometry imaging proves differential absorption
profiles of well-characterised permeability markers along the crypt-villus
axis. Sci Rep. 2017;7:6352.
33. Goodwin RJ, Bunch J, McGinnity DF. Mass spectrometry imaging in
oncology drug discovery. Adv Cancer Res. 2017;134:133–71.
34. Dexter A, Race AM, Steven RT, Barnes JR, Hulme H, Goodwin RJA, Styles IB,
Bunch J. Two-phase and graph-based clustering methods for accurate and
efficient segmentation of large mass spectrometry images. Anal Chem.
2017;89:11293–300.
35. Jones EE, Zhang W, Zhao X, Quiason C, Dale S, Shahidi-Latham S, Grabowski
GA, Setchell KDR, Drake RR, Sun Y. Tissue localization of glycosphingolipid
accumulation in a Gaucher disease mouse brain by LC-ESI-MS/MS and high-
resolution MALDI imaging mass spectrometry. SLAS Discov. 2017; https://
doi.org/10.1177/2472555217719372.
36. Jones EE, Quiason C, Dale S, Shahidi-Latham SK. Feasibility assessment of a
MALDI FTICR imaging approach for the 3D reconstruction of a mouse lung.
J Am Soc Mass Spectrom. 2017;28:1709–15.
37. Salphati L, Alicke B, Heffron TP, Shahidi-Latham S, Nishimura M, Cao T,
Carano RA, Cheong J, Greve J, Koeppen H, et al. Brain distribution and
efficacy of the brain penetrant PI3K inhibitor GDC-0084 in Orthotopic
mouse models of human glioblastoma. Drug Metab Dispos. 2016;44:1881–9.
38. Choo EF, Ly J, Chan J, Shahidi-Latham SK, Messick K, Plise E, Quiason CM,
Yang L. Role of P-glycoprotein on the brain penetration and brain
pharmacodynamic activity of the MEK inhibitor cobimetinib. Mol Pharm.
2014;11:4199–207.
39. Salphati L, Shahidi-Latham S, Quiason C, Barck K, Nishimura M, Alicke B,
Pang J, Carano RA, Olivero AG, Phillips HS. Distribution of the
phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in
U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted
laser desorption ionization imaging. Drug Metab Dispos. 2014;42:1110–6.
40. Galea D, Inglese P, Cammack L, Strittmatter N, Rebec M, Mirnezami R,
Laponogov I, Kinross J, Nicholson J, Takats Z, Veselkov KA. Translational
utility of a hierarchical classification strategy in biomolecular data analytics.
Sci Rep. 2017;7:14981.
Charkoftaki et al. Human Genomics  (2018) 12:10 Page 6 of 6
